Commission Delegated Regulation (EU) 2022/692 of 16 February 2022 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

ANNEX
ANNEX
Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
(1)
in Part 3, Table 3 is amended as follows:
(a)
the following entries are inserted:
Index No
Chemical Name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M- factors and ATE
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘014-052-00-7
silanamine, 1,1,1-trimethyl- N -(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide
272-697-1
68909-20-6
STOT RE 2
H373 (lungs) (inhalation)
GHS08
Wng
H373 (lungs) (inhalation)
EUH066’
‘035-005-00-7
ammonium bromide
235-183-8
12124-97-9
Repr. 1B
Lact.
STOT SE 3
STOT RE 1
Eye Irrit. 2
H360FD
H362
H336
H372 (nervous system)
H319
GHS08
GHS07
Dgr
H360FD
H362
H336
H372 (nervous system)
H319’
‘050-032-00-4
dibutyltin bis(2-ethylhexanoate)
220-481-2
2781-10-4
Muta. 2
Repr. 1B
STOT RE 1
H341
H360FD
H372 (immune system)
GHS08
Dgr
H341
H360FD
H372 (immune system)’
‘050-033-00-X
dibutyltin di(acetate)
213-928-8
1067-33-0
Muta 2
Repr. 1B
STOT RE 1
H341
H360FD
H372 (immune system)
GHS08
Dgr
H341
H360FD
H372 (immune system)’
‘052-001-00-0
tellurium
236-813-4
13494-80-9
Repr. 1B
Lact.
H360Df
H362
GHS08
Dgr
H360Df
H362’
‘052-002-00-6
tellurium dioxide
231-193-1
7446-07-3
Repr. 1B
Lact.
H360Df
H362
GHS08
Dgr
H360Df
H362’
‘056-005-00-3
barium diboron tetraoxide
237-222-4
13701-59-2
Repr. 1B
Acute Tox. 4
Acute Tox. 3
H360FD
H332
H301
GHS08
GHS06
Dgr
H360FD
H332
H301
inhalation:
ATE = 1,5 mg/L (dusts or mists)
oral:
ATE = 100 mg/kg bw’
‘601-097-00-8
Propylbenzene
203-132-9
103-65-1
Flam. Liq. 3
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2
H226
H304
H335
H411
GHS02
GHS08
GHS07
GHS09
Dgr
H226
H304
H335
H411’
‘603-243-00-6
2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol
253-057-0
36483-57-5; 1522-92-5
Carc. 1B
Muta. 2
H350
H341
GHS08
Dgr
H350
H341’
‘604-096-00-0
piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
200-076-7
51-03-6
STOT SE 3
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H335
H319
H400
H410
GHS07
GHS09
Wng
H335
H319
H410
EUH066
M = 1
M = 1’
‘604-097-00-6
2,4,6-tri- tert -butylphenol
211-989-5
732-26-3
Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Sens. 1B
H360D
H302
H373 (liver)
H317
GHS08
GHS07
Dgr
H360D
H302
H373 (liver)
H317
oral:
ATE = 500 mg/kg bw’
‘604-098-00-1
4,4'-sulphonyldiphenol; bisphenol S
201-250-5
80-09-1
Repr. 1B
H360FD
GHS08
Dgr
H360FD’
‘606-153-00-5
benzophenone
204-337-6
119-61-9
Carc. 1B
H350
GHS08
Dgr
H350’
‘606-154-00-0
quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone
220-529-2
2797-51-5
Carc. 2
Repr. 2
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H351
H361d
H302
H373 (blood system, kidneys)
H319
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361d
H302
H373 (blood system, kidneys)
H319
H317
H410
oral:
ATE = 500 mg/kg bw
M = 10
M = 10’
‘607-756-00-6
exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate
227-561-6
5888-33-5
Skin Sens. 1A
H317
GHS07
Wng
H317’
‘607-757-00-1
daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N -dimethylaminosuccinamic acid
216-485-9
1596-84-5
Carc. 2
H351
GHS08
Wng
H351’
‘607-758-00-7
4,4'-oxydi(benzenesulphonohydrazide)
201-286-1
80-51-3
Self-react. D
Aquatic Acute 1
Aquatic Chronic 1
H242
H400
H410
GHS02
GHS09
Dgr
H242
H410
M = 1
M = 1’
‘607-759-00-2
toluene-4-sulphonohydrazide
216-407-3
1576-35-8
Self-react. D
H242
GHS02
Dgr
H242’
‘607-760-00-8
2-[ N -ethyl-4-[(5-nitrothiazol-2-yl)azo]- m -toluidino]ethyl acetate; C.I. Disperse Blue 124
239-203-6
15141-18-1
Skin Sens. 1A
H317
GHS07
Wng
H317
Skin Sens. 1A; H317: C ≥ 0,001 %’
‘607-761-00-3
Perfluoroheptanoic acid; tridecafluoroheptanoic acid
206-798-9
375-85-9
Repr. 1B
STOT RE 1
H360D
H372 (liver)
GHS08
Dgr
H360D
H372 (liver)’
‘607-762-00-9
methyl N -(isopropoxycarbonyl)- L -valyl-(3 RS )-3-(4-chlorophenyl)- β -alaninate; valifenalate
-
283159-90-0
Carc. 2
Aquatic Chronic 2
H351
H411
GHS08
GHS09
Wng
H351
H411’
‘607-763-00-4
6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts
-
-
Repr. 1B
Eye Irrit. 2
H360FD
H319
GHS08
GHS07
Dgr
H360FD
H319’
‘607-764-00-X
6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid
-
2156592-54-8
Repr. 1B
Eye Irrit. 2
H360FD
H319
GHS08
GHS07
Dgr
H360FD
H319’
‘607-765-00-5
6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid
-
-
Repr. 1B
H360FD
GHS08
Dgr
H360FD’
‘613-341-00-0
clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine
277-728-2
74115-24-5
Aquatic Chronic 1
H410
GHS09
Wng
H410
M = 1’
‘613-342-00-6
theophylline; 1,3-dimethyl-3,7-dihydro-1 H -purine-2,6-dione
200-385-7
58-55-9
Repr. 1B
H360D
GHS08
Dgr
H360D’
‘613-343-00-1
pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether
-
179101-81-6
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 1 000
M = 100’
‘613-344-00-7
Pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione
223-296-5;
240-062-8
3811-73-2;
15922-78-8
Acute Tox. 3
Acute Tox. 3
Acute Tox. 4
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 2
H331
H311
H302
H372 (nervous system)
H315
H319
H317
H400
H411
GHS06
GHS08
GHS09
Dgr
H331
H311
H302
H372 (nervous system)
H315
H319
H317
H410
EUH070
inhalation:
ATE = 0,5 mg/L (dusts or mists)
dermal:
ATE = 790 mg/kg bw
oral:
ATE = 500 mg/kg bw
M = 100’
‘613-345-00-2
1,3,5-triazine-2,4,6-triamine;
melamine
203-615-4
108-78-1
Carc. 2
STOT RE 2
H351
H373 (urinary tract)
GHS08
Wng
H351
H373 (urinary tract)’
‘615-046-00-2
1,3-bis(1-isocyanato-1-methylethyl)benzene; [ m -TMXDI]
220-474-4
2778-42-9
Resp. Sens. 1
Skin Sens. 1A
H334
H317
GHS08
Dgr
H334
H317’
‘615-047-00-8
1,3-bis(isocyanatomethyl)benzene; [ m -XDI]
222-852-4
3634-83-1
Resp. Sens. 1
Skin Sens. 1A
H334
H317
GHS08
Dgr
H334
H317
Skin Sens. 1A; H317: C ≥ 0,001 %’
‘615-048-00-3
2,4,6-triisopropyl- m -phenylene diisocyanate
218-485-4
2162-73-4
Resp. Sens. 1
Skin Sens. 1
H334
H317
GHS08
Dgr
H334
H317’
‘615-049-00-9
1,5-naphthylene diisocyanate
[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]
221-641-4
3173-72-6
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3
H335
H315
H319
H334
H317
H412
GHS07
GHS08
Dgr
H335
H315
H319
H334
H317
H412’
‘615-050-00-4
1,5-naphthylene diisocyanate
[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]
221-641-4
3173-72-6
Acute Tox. 2
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3
H330
H335
H315
H319
H334
H317
H412
GHS06
GHS08
Dgr
H330
H335
H315
H319
H334
H317
H412
inhalation:
ATE = 0,27 mg/L (dusts or mists)’
‘616-237-00-3
fluopicolide (ISO); 2,6-dichloro- N -[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide
-
239110-15-7
Repr. 2
H361d
GHS08
Wng
H361d’
‘616-238-00-9
N -(2-nitrophenyl)phosphoric triamide
477-690-9
874819-71-3
Repr. 1B
STOT RE 2
H360Fd
H373 (kidneys)
GHS08
Dgr
H360Fd
H373 (kidneys)’
‘616-239-00-4
N -(5-chloro-2-isopropylbenzyl)- N -cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1 H -pyrazole-4-carboxamide; isoflucypram
-
1255734-28-1
Repr. 2
Acute Tox. 4
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H361f
H332
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361f
H332
H317
H410
inhalation:
ATE = 2,2 mg/L (dusts or mists)
M = 10
M = 1’
‘616-240-00-X
Reaction mass of 3-(difluoromethyl)-1-methyl- N -[(1 RS ,4 SR ,9 RS )-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl- N -[(1 RS ,4 SR ,9 SR )-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam
-
881685-58-1
Carc. 2
Repr. 1B
Skin Sens. 1B
Aquatic Acute 1 Aquatic Chronic 1
H351
H360D
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H351
H360D
H317
H410
Repr. 1B; H360D:
C ≥ 3 %
M = 10
M = 10’
‘650-058-00-1
Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents]
283-644-7
84696-25-3
Repr. 2
Skin Sens. 1
Aquatic Chronic 1
H361d
H317
H410
GHS08
GHS07
GHS09
Wng
H361d
H317
H410
M = 10’
(b)
the entries corresponding to index numbers 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 are replaced by the following entries respectively:
Index No
Chemical Name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M- factors and ATE
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘014-001-00-9
trichlorosilane
233-042-5
10025-78-2
Flam. Liq. 1
Water-react. 1
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1A
Eye Dam. 1
H224
H260
H331
H302
H314
H318
GHS02
GHS06
GHS05
Dgr
H224
H260
H331
H302
H314
EUH014
EUH029
EUH071
inhalation:
ATE = 7,6 mg/L (vapour)
oral:
ATE = 1 000 mg/kg bw’
‘023-001-00-8
divanadium pentaoxide; vanadium pentoxide
215-239-8
1314-62-1
Muta. 2
Carc. 1B
Repr. 2
Lact.
Acute Tox. 3
Acute Tox. 2
STOT SE 3
STOT RE 1
Aquatic Chronic 2
H341
H350
H361fd
H362
H301
H330
H335
H372 (respiratory tract, inhalation)
H411
GHS06
GHS08
GHS09
Dgr
H341
H350
H361fd
H362
H301
H330
H335
H372 (respiratory tract, inhalation)
H411
inhalation:
ATE = 0,05 mg/L (dusts or mists)
oral:
ATE = 220 mg/kg bw’
‘601-024-00-X
Cumene
202-704-5
98-82-8
Flam. Liq. 3
Carc. 1B
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2
H226
H350
H304
H335
H411
GHS02
GHS08
GHS07
GHS09
Dgr
H226
H350
H304
H335
H411’
‘603-014-00-0
2-butoxyethanol; ethylene glycol monobutyl ether
203-905-0
111-76-2
Acute Tox. 3
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2
H331
H302
H315
H319
GHS06
Dgr
H331
H302
H315
H319
inhalation:
ATE = 3 mg/L (Vapours)
oral:
ATE = 1 200 mg/kg bw’
‘603-107-00-6
2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether
203-906-6
111-77-3
Repr. 1B
H360D
GHS08
Dgr
H360D
Repr. 1B; H360D: C ≥ 3 %’
‘604-030-00-0
4,4'-isopropylidenediphenol; bisphenol A
201-245-8
80-05-7
Repr. 1B
STOT SE 3
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H360F
H335
H318
H317
H400
H410
GHS08
GHS07
GHS05
GHS09
Dgr
H360F
H335
H318
H317
H410
M = 1
M = 10’
‘607-111-00-9
2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate;
trimethylolpropane triacrylate
239-701-3
15625-89-5
Carc. 2
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H315
H319
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H315
H319
H317
H410
M = 1
M = 1
D’
‘607-230-00-6
2-ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex
-
-
Repr. 1B
H360D
GHS08
Dgr
H360D’
‘607-253-00-1
cyfluthrin (ISO); α -cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate
269-855-7
68359-37-5
Lact.
Acute Tox. 2
Acute Tox. 2
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1
H362
H330
H300
H370 (nervous system)
H400
H410
GHS06
GHS08
GHS09
Dgr
H362
H330
H300
H370 (nervous system)
H410
inhalation:
ATE = 0,14 mg/L (dusts or mists)
oral:
ATE = 14 mg/kg bw
M = 1 000 000
M = 1 000 000 ’
‘607-254-00-7
beta-cyfluthrin (ISO); reaction mass of rel-( R )-cyano(4-fluoro-3-phenoxyphenyl)methyl (1 S ,3 S )-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-( R )-cyano(4-fluoro-3-phenoxyphenyl)methyl (1 S ,3 R )-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate
-
1820573-27-0
Lact.
Acute Tox. 2
Acute Tox. 2
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1
H362
H330
H300
H370 (nervous system)
H400
H410
GHS06
GHS08
GHS09
Dgr
H362
H330
H300
H370 (nervous system)
H410
inhalation:
ATE = 0,081 mg/L (dusts or mists)
oral:
ATE = 11 mg/kg bw
M = 1 000 000
M = 1 000 000 ’
‘607-734-00-6
pentapotassium 2,2',2",2"',2""-(ethane-1,2-diylnitrilo)pentaacetate
404-290-3
7216-95-7
Repr. 1B
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
H360D
H332
H373 (inhalation)
H319
GHS08
GHS07
Dgr
H360D
H332
H373 (inhalation)
H319
Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’
‘607-735-00-1
N -carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid)
200-652-8
67-43-6
Repr. 1B
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
H360D
H332
H373 (inhalation)
H319
GHS08
GHS07
Dgr
H360D
H332
H373 (inhalation)
H319
Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’
‘607-736-00-7
pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate
205-391-3
140-01-2
Repr. 1B
Acute Tox. 4
STOT RE 2
H360D
H332
H373 (inhalation)
GHS08
GHS07
Dgr
H360D
H332
H373 (inhalation)
Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’
‘608-032-00-2
acetamiprid (ISO); (1 E )- N -[(6-chloropyridin-3-yl)methyl]- N’ -cyano- N -methylethanimidamide; ( E )- N 1-[(6-chloro-3-pyridyl)methyl]- N 2-cyano- N 1-methylacetamidine
-
135410-20-7 160430-64-8
Repr. 2
Acute Tox. 3
Aquatic Chronic 1
Aquatic Acute 1
H361d
H301
H410
H400
GHS08
GHS06
GHS09
Dgr
H361d
H301
H410
oral:
ATE = 140 mg/kg bw
M = 10
M = 10’
‘609-042-00-X
pendimethalin (ISO); N -(1-ethylpropyl)-2,6-dinitro-3,4-xylidene
254-938-2
40487-42-1
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H400
H410
GHS08
GSH09
Wng
H361d
H410
M = 100
M = 10’
‘613-012-00-1
bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide
246-585-8
25057-89-0
Repr. 2
Acute Tox. 4
Eye Irrit. 2
Skin Sens. 1
H361d
H302
H319
H317
GHS08
GHS07
Wng
H361d
H302
H319
H317
oral: ATE = 1 600 mg/kg bw’
‘616-164-00-7
dimoxystrobin (ISO); (2 E )-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)- N -methylacetamide; ( E )-2-(methoxyimino)- N -methyl-2-[ α -(2,5-xylyloxy)- o -tolyl]acetamide
149961-52-4
Carc. 2
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H351
H361d
H332
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361d
H332
H410
inhalation:
ATE = 1,3 mg/L (dusts or mists)
M = 100
M = 100’
(c)
the entry corresponding to index number 615-007-00-X is deleted.
Schedules & Appendices

Cite this act
